Tony Arulanandam

Company: Synaptimmune Therapeutics

Job title: CEO and Founder

Seminars:

Unlocking the Potential of CAR-NK Approaches for Enhanced Tumor Recognition 1:00 pm

Discussing IDR regions engineered into CAR constructs with preclinical proof of concept showing increased condensate formation, signaling, potency and high antigen sensitivity compared to current 3rd generation CAR constructs against antigen low and high solid tumor and blood cancers Developing allogeneic off the shelf approaches in both T-cells and NK cells for use in cancer and autoimmunityRead more

day: Day Two - Track A PM